Studies have identified an expansion of NKG2C+CD57+FcεRIγ− memory NK cells in COVID-19 patients, particularly in individuals with prior HCMV infection, suggesting potential cross-reactivity and enhanced antiviral effects [60]. This evidence concerns the gene B3GAT1 and cytomegalovirus infection.